SynaptixBio Ltd.
- Biotech or pharma, therapeutic R&D
SynaptixBio is a rare disease biotech pioneering ground-breaking development for treatment of severe leukodystrophies. Leukodystrophies affect the brain and manifest with a spectrum of severity and symptoms. Onset is typically recognised in toddlers with development delays and deterioration of motor function (gait dysfunction and difficulties with sitting, speech and swallowing). Often survival is limited to young adulthood.
Synaptix is targeting a specific subset of leukodystrophies by reducing the expression of a mutated gene (TUBB4A) which causes the disease.
Address
Harwell CampusOxfordshire
United Kingdom
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}